Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
about
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Nab-paclitaxel plus either gem ...... bel, randomised phase 2 trial.
@ast
Nab-paclitaxel plus either gem ...... bel, randomised phase 2 trial.
@en
type
label
Nab-paclitaxel plus either gem ...... bel, randomised phase 2 trial.
@ast
Nab-paclitaxel plus either gem ...... bel, randomised phase 2 trial.
@en
prefLabel
Nab-paclitaxel plus either gem ...... bel, randomised phase 2 trial.
@ast
Nab-paclitaxel plus either gem ...... bel, randomised phase 2 trial.
@en
P2093
P50
P1476
Nab-paclitaxel plus either gem ...... bel, randomised phase 2 trial.
@en
P2093
Amandine Monier
Aurélia Meurisse
Benoist Chibaudel
Christophe Louvet
Christophe Tournigand
Franck Bonnetain
Jean-François Seitz
Julien Volet
Jérome Dauba
Jérôme Desramé
P304
P356
10.1016/S2468-1253(17)30046-8
P577
2017-02-28T00:00:00Z